Vascular endothelial growth inhibitor in human cancer (Review)

Zhang, Ning, Sanders, Andrew James ORCID: https://orcid.org/0000-0002-7997-5286, Ye, Lin ORCID: https://orcid.org/0000-0002-0303-2409 and Jiang, Wen G. ORCID: https://orcid.org/0000-0002-3283-1111 2009. Vascular endothelial growth inhibitor in human cancer (Review). International Journal of Molecular Medicine 24 (1) , pp. 3-8. 10.3892/ijmm_00000198

Preview

PDF Download (99kB) | Preview

Abstract

Vascular endothelial growth inhibitor (VEGI), also known as tumour necrosis factor superfamily member 15 (TNFSF15) and TNF ligand related molecule 1 (TL1), is a recently identified anti-angiogenic cytokine that belongs to the TNF superfamily. Three isoforms of VEGI, VEGI 174, 192, and 251 have been documented, all sharing 151 common C-terminal amino acids but differing in their N-terminal regions. The investigations into the biological functions of VEGI have pointed to a potential cancer inhibitory role for the cytokine. The inhibitory effects of VEGI on cancer are manifested in three main areas, the direct effect on cancer cells, the anti-angiogenic effects on endothelial cells, and stimulation of maturation of dendric cells. The clinical aspect of VEGI in cancer is also being explored in recent years. The present article overviews the recent progress on this molecule and discusses the value of VEGI as a potential therapeutic target in cancer therapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Spandidos Publications
ISSN:	1107-3756
Last Modified:	22 May 2023 16:54
URI:	https://orca.cardiff.ac.uk/id/eprint/17970

Citation Data

Cited 27 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item